Enveric Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
ENVB$1.44+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| As of December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash | $2,287,977 | $17,723,884 |
| Prepaid expenses and other current assets | 1,293,554 | 708,053 |
| Total current assets | 3,581,531 | 18,431,937 |
| Other assets: | ||
| Property and equipment, net | 507,377 | 677,485 |
| Right-of-use operating lease asset | — | 63,817 |
| Intangible assets, net | 210,932 | 379,686 |
| Total other assets | 718,309 | 1,120,988 |
| Total assets | $4,299,840 | $19,552,925 |
| LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,218,783 | $463,275 |
| Accrued liabilities | 1,075,643 | 1,705,655 |
| Current portion of right-of-use operating lease obligation | — | 63,820 |
| Investment option liability | 23,608 | 851,008 |
| Warrant liability | 25,470 | 185,215 |
| Derivative liability | — | 727,000 |
| Total current liabilities | 2,343,504 | 3,995,973 |
| Commitments and contingencies (Note 10) | - | - |
| Mezzanine equity | ||
| Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Redeemable non-controlling interest | — | 885,028 |
| Total mezzanine equity | — | 885,028 |
| Shareholders’ equity | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Common stock, $0.01 par value, 100,000,000 shares authorized, 2,739,315 and 2,078,271 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 27,392 | 20,782 |
| Additional paid-in capital | 100,815,851 | 94,395,662 |
| Stock subscription receivable | (1,817,640) | — |
| Accumulated deficit | (96,499,518) | (79,207,786) |
| Accumulated other comprehensive loss | (569,749) | (536,734) |
| Total shareholders’ equity | 1,956,336 | 14,671,924 |
| Total liabilities, mezzanine equity, and shareholders’ equity | $4,299,840 | $19,552,925 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.